Referred to the House Committee on Energy and Commerce.
This resolution expresses the House's support for designating June 19, 2025 as World Sickle Cell Awareness Day and highlights the need for research, early screening, new treatments, and equitable access. It calls on the Department of Health and Human Services to develop global policy solutions and encourages the President to form an interagency group to address access and bias in care. The resolution is a formal statement of priorities by the House and does not create binding law or new funding.
This is a simple House resolution that only applies to the House of Representatives; it does not go to the Senate or the President and is not legally binding. It is adopted under normal House procedures and does not itself change federal law or appropriate money.
This House resolution supports designating June 19, 2025, as “World Sickle Cell Awareness Day” to raise awareness of sickle cell disease (SCD) and sickle cell trait (SCT).
It highlights prevalence, morbidity, existing gaps in screening and treatment, recent FDA approvals of genetic therapies, and the need for more research, early detection, and preventive care.
The resolution calls on HHS to develop global policy solutions, encourages events to raise awareness, supports removing barriers to equitable access to innovative therapies (including cell-, gene-, and gene-editing therapies) in Medicare and Medicaid, and urges the President to form an interagency Sickle Cell Disease Group to pursue equitable access and address healthcare bias.
By content alone the measure is highly likely to be adopted as a House simple resolution because it is symbolic and nonbinding; however, simple House resolutions do not become law and do not require Senate or Presidential action. The chance of this specific text (an H.Res.) becoming binding federal law is therefore near zero. If the practical goal is raising awareness or prompting agency action, the resolution could succeed as a political signal, but it does not itself create enforceable legal changes or funding.
Relative to its intended legislative type, this bill functions primarily as a commemorative resolution that clearly states the problem and expresses support for awareness, while also incorporating non‑binding administrative requests directed at federal agencies and the President.
Scope and pace of federal involvement: liberals favor proactive federal action and funding; conservatives worry about expanded federal programs and bureaucracy.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and pace of federal involvement: liberals favor proactive federal action and funding; conservatives worry about expanded federal programs and bureaucracy.
A mainstream progressive would view the resolution positively as a needed effort to center a disease that disproportionately affects Black and other historically marginalized communities.
They would welcome the emphasis on equity, early detection, research, and access to cutting‑edge therapies, and see the interagency coordination call as a constructive step.
They would likely press for concrete follow‑through: funding, targeted outreach, removal of systemic bias, and measures to ensure approved curative therapies are affordable and accessible.
A pragmatic moderate would generally support the resolution as a non‑controversial step to spotlight a serious public‑health issue and to encourage federal coordination.
They would appreciate the focus on newborn screening, research, and interagency collaboration, but would want clarity on costs, implementation, and oversight.
The centrist would favor measured follow‑up actions—targeted pilot programs, evidence‑driven expansions, and cost‑effectiveness analysis—over broad open‑ended commitments.
A mainstream conservative is likely to support the awareness and research aspects but be cautious about the resolution’s calls to expand access in Medicare and Medicaid to expensive cell and gene therapies and to broaden federal coordination.
They would view the designation and encouragement of awareness events as benign, but express concern about implied expansions of federal entitlement coverage, potential high costs, and additional bureaucracy through an interagency group.
Ethical questions about gene‑editing could be raised, and conservatives may insist any policy changes respect fiscal constraints and state roles.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
By content alone the measure is highly likely to be adopted as a House simple resolution because it is symbolic and nonbinding; however, simple House resolutions do not become law and do not require Senate or Presidential action. The chance of this specific text (an H.Res.) becoming binding federal law is therefore near zero. If the practical goal is raising awareness or prompting agency action, the resolution could succeed as a political signal, but it does not itself create enforceable legal changes or funding.
The bill has not accumulated any surfaced votes yet.
Scope and pace of federal involvement: liberals favor proactive federal action and funding; conservatives worry about expanded federal prog…
By content alone the measure is highly likely to be adopted as a House simple resolution because it is symbolic and nonbinding; however, si…
Relative to its intended legislative type, this bill functions primarily as a commemorative resolution that clearly states the problem and expresses support for awareness, while also incorporating non‑binding administra…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.